Skip to main content

Advertisement

SpringerLink
Log in

Use of monoclonal antibodies for metastatic colorectal cancer in the andalusian public health system

  • Short Research Report
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background The place of monoclonal antibodies in metastatic colorectal cancer has not been clearly defined. Objective To determine the treatment pattern of monoclonal antibodies in colorectal cancer patients in the Andalusian Public Healthcare System. Method Data were collected from all patients treated with these drugs from July 2009 to December 2010 from pharmacy programs and medical records. Results Three hundred patients were included, of whom 227 received the antibody at the forefront. The proportion of patients who received bevacizumab in the first line is greater than that of cetuximab (62.1 vs. 37.5 % respectively) and similar in the second line and subsequent (47.8 vs. 53.8 % and 48.5 vs. 46.2 % respectively). XELOXbevacizumab was the most frequently prescribed scheme (35.3 %) followed by FOLFOX-monoclonal antibody schemes, regardless that this was bevacizumab or cetuximab (22.5 %). The median progression free survival (PFS) was 11.7 months for patients receiving cetuximab, 9.6 months for patients receiving bevacizumab and 8.2 months for those who received no monoclonal antibody in the first line. Conclusion Bevacizumab was the antibody of choice in first line, showing utilization rates similar to cetuximab in second line and subsequent. The median PFS in our study is related to the PFS of the major clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Corral MJ, Clopés A, Navarro M, Germà JR, Borràs JM. Impact on budget of new drugs for colorectal cancer treatment. Med Clin (Barc). 2007;129:134–7.

    Article  Google Scholar 

  2. Hess GP, Wang PF, Quach D, Barber B, Zhao Z. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract. 2010;6:301–7.

    Article  PubMed  Google Scholar 

  3. Zhao Z, Pelletier E, Barber B, Bhosle M, Wang S, Gao S, et al. Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe. Curr Med Res Opin. 2012;28:221–9.

    Article  PubMed  CAS  Google Scholar 

  4. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–37.

    Article  PubMed  CAS  Google Scholar 

  5. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol. 2005;23:4866–75.

    Article  PubMed  CAS  Google Scholar 

  6. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.

    Article  PubMed  CAS  Google Scholar 

  7. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007;25:4779–86.

    Article  PubMed  CAS  Google Scholar 

  8. Van Cutsem E, Köhne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011–9.

    Article  PubMed  Google Scholar 

  9. Sargent DJ, Köhne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol. 2009;27:1948–55.

    Article  PubMed  Google Scholar 

  10. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009;14:862–70.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

All pharmacists who have collaborated on the project: Garrido MT, Garrido M, Vallejo I, Martínez MJ, Martínez C, Mora B, Gavira R, Jimenez R, Nieto F, Garrido R, García-Pelayo N, Muñoz N, Gordillo E, Marín JF, Mora MA, Férnandez JJ, Zaragoza M, Muro B, Nacle I, Gago AI, Damas M.

Funding

This study was supported by the Health Department of the Spanish Government. (Investigación Clínica Independiente. Ministerio de Sanidad y Política Social).

Conflicts of interest

The authors declare that they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Unidad de Gestión Clínica Farmacia Hospitalaria, Hospital Universitario Virgen del Rocío, Avda. Manuel Siurot s/n. 41013, Sevilla, Spain

    Bernardo Santos-Ramos, Rocío Fernández-Fernández, María Espinosa-Bosch & Javier Bautista-Paloma

  2. Subdirección de Farmacia y Prestaciones, Servicio Andaluz de Salud, Sevilla, Spain

    Roberto Marín-Gil

  3. Centro Superior de Investigación en Salud Pública (CSISP), Valencia, Spain

    Salvador Peiró-Moreno

  4. Departamento de Farmacología, Facultad de Farmacia, Sevilla, Spain

    Concepción Pérez-Guerrero

Authors
  1. Bernardo Santos-Ramos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rocío Fernández-Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberto Marín-Gil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. María Espinosa-Bosch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Salvador Peiró-Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Concepción Pérez-Guerrero
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Javier Bautista-Paloma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernardo Santos-Ramos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Santos-Ramos, B., Fernández-Fernández, R., Marín-Gil, R. et al. Use of monoclonal antibodies for metastatic colorectal cancer in the andalusian public health system. Int J Clin Pharm 35, 550–553 (2013). https://doi.org/10.1007/s11096-013-9791-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-013-9791-y

Keywords

Search

Navigation